Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Pfizer Q3 profit...

    Pfizer Q3 profit doubles to $2.8 billion, raises full-year revenue forecast

    Written by supriya kashyap kashyap Published On 2017-11-02T12:33:22+05:30  |  Updated On 2 Nov 2017 12:33 PM IST
    Pfizer Q3 profit doubles to $2.8 billion, raises full-year revenue forecast

    New York: US pharmaceutical giant Pfizer reported that third-quarter profit more than doubled as strength in newer drugs to treat cancer and other illnesses offset the hit from patent expirations.


    Net income came in at $2.8 billion, compared with just under $1.4 billion in the year-ago period, a quarter that was hit with one-time expenses connected to Pfizer acquisitions.


    Revenues edged up 0.9% to $13.2 billion.


    Pfizer’s earnings jumped in the “innovative health” division, which commercializes newer products, such as the Ibrance capsules for breast cancer, the anticoagulant Eliquis and the rheumatoid arthritis drug Xeljanz.


    Those gains were offset by a similarly-sized decline in Pfizer’s legacy brand business, called “essential health.” Pfizer cited declines in some drugs, such as the antidepressant Pristiq in the United States and said product shortages of injectable drugs under the Hospira brand had also hit sales.


    Pfizer lifted its full-year forecast to $2.58 to $2.62 per share from the previous range of $2.54 to $2.60 per share.


    Chief executive Ian Read said the company was positioned for long-term success, citing two trends: “an expected decline in the unfavourable revenue impact associated with product losses of exclusivity and the beginning of an expected multiyear wave of potential new product launches and product line extensions driven by our pipeline.”


    Shares rose 1.1% in pre-market trading to $35.52.

    breast cancercancerEliquishospiraIan ReadPfizerrheumatoid arthritisXeljanz
    Source : AFP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok